Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Restricted Stock Units |
284 K |
$12 M |
$42.24 |
Jan 19, 2024 |
Direct |
Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Common Stock |
160 K |
$6.78 M |
$42.24 |
Dec 19, 2023 |
Direct |
Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Common Stock |
83.9 K |
$3.54 M |
$42.24 |
Dec 19, 2023 |
By Trust |
Atara Biotherapeutics, Inc. |
Director |
Common Stock |
31.5 K |
$12.3 K |
$0.39 |
Jun 23, 2022 |
Direct |
Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Stock Option (Right to Buy) |
216 K |
|
|
Jun 12, 2023 |
Direct |
Cerevel Therapeutics Holdings, Inc. |
President & CEO, Director |
Performance-based Restricted Stock Units |
160 K |
|
|
Jun 12, 2023 |
Direct |
Atara Biotherapeutics, Inc. |
Director |
Non-Qualified Stock Option (Right to Buy) |
31.5 K |
|
|
Jun 23, 2022 |
Direct |
Ikena Oncology, Inc. |
Director |
Stock Option (Right to Buy) |
13.4 K |
|
|
Jun 9, 2022 |
Direct |
Translate Bio, Inc. |
Chief Executive Officer, Director |
Common Stock |
0 |
|
|
Sep 14, 2021 |
By Ronald C. Renaud, Jr. Trust - 2007 |
Translate Bio, Inc. |
Chief Executive Officer, Director |
Common Stock |
0 |
|
|
Sep 14, 2021 |
By Ronald Renaud 2014 Irrevocable Family Trust |
Translate Bio, Inc. |
Chief Executive Officer, Director |
Common Stock |
0 |
|
|
Sep 14, 2021 |
Direct |
Translate Bio, Inc. |
Chief Executive Officer, Director |
Stcok Option (right to buy) |
0 |
|
|
Sep 14, 2021 |
Direct |
Translate Bio, Inc. |
Chief Executive Officer, Director |
Stock Option (right to buy) |
0 |
|
|
Sep 14, 2021 |
Direct |